Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study

Cardiovascular Diabetology

Original Investigation

Wolfgang Koenig¹  Wolfgang Rathmann²  Annette Peters³  Barbara Thorand³  Cornelia Huth³  Christa Meisinger³  Maren Carstensen-Kirberg⁴  Julia M. Kannenberg⁴  Christian Herder⁴  Michael Roden⁵ 

[1] Deutsches Herzzentrum München, Technische Universität München, Munich, Germany;German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany;German Center for Diabetes Research (DZD), München-Neuherberg, Germany;Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany;German Center for Diabetes Research (DZD), München-Neuherberg, Germany;Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany;Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225, Düsseldorf, Germany;German Center for Diabetes Research (DZD), München-Neuherberg, Germany;Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225, Düsseldorf, Germany;German Center for Diabetes Research (DZD), München-Neuherberg, Germany;Department of Endocrinology and Diabetology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany;

关键词: Inflammation;    Interleukin-22;    Cytokine;    Type 2 diabetes;    Cardiometabolic risk;    Cohort study;   

DOI  :  10.1186/s12933-017-0498-6

 received in 2016-12-06, accepted in 2017-01-13,  发布年份 2017

来源: Springer

【 摘 要 】

AimsInterleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-22 levels are associated with lower diabetes incidence.MethodsCross-sectional associations between serum IL-22, cardiometabolic risk factors and glucose tolerance status were investigated in 1107 persons of the population-based KORA F4 study. The prospective association between serum IL-22 and incident type 2 diabetes was assessed in 504 initially non-diabetic study participants in both the KORA F4 study and its 7-year follow-up examination KORA FF4, 76 of whom developed diabetes.ResultsMale sex, current smoking, lower HDL cholesterol, lower estimated glomerular filtration rate and higher serum interleukin-1 receptor antagonist were associated with higher IL-22 levels after adjustment for confounders (all P < 0.05). Serum IL-22 showed no associations with glucose tolerance status, prediabetes or type 2 diabetes. Baseline serum IL-22 levels (median, 25th/75th percentiles) for incident type 2 diabetes cases and non-cases were 6.28 (1.95; 12.35) and 6.45 (1.95; 11.80) pg/ml, respectively (age and sex-adjusted P = 0.744). The age and sex-adjusted OR (95% CI) per doubling of IL-22 for incident type 2 diabetes of 1.02 (0.85; 1.23) was almost unchanged after consideration of further confounders.ConclusionsHigh serum levels of IL-22 were positively rather than inversely associated with several cardiometabolic risk factors. However, these associations did not translate into an increased risk for type 2 diabetes. Thus, our data argue against the utility of IL-22 as biomarker for prevalent or incident type 2 diabetes in humans, but identify potential determinants of IL-22 levels which merits further research in the context of cardiovascular diseases.

【 授权许可】

CC BY   
© The Author(s) 2017